{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:40:02Z","timestamp":1745768402261,"version":"3.40.4"},"reference-count":11,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>Myelofibrosis, either primary or resulting from essential thrombocythemia or polycythemia vera, may present with highly variable white blood cell counts, including progressive leukopaenia with its associated risk of infections. Medications have been developed to reduce splenomegaly and other symptoms, but there are no reports of improved white blood cell counts. We report a case of primary myelofibrosis with marked improvement in leukopaenia and reduced recurrent infections, in addition to reduction in spleen size and improvement in disease-associated symptoms, within 20\u2005weeks after using low-dose ruxolitinib. Although reduction of splenomegaly in myelofibrosis patients is the anticipated benefit of ruxolitinib, the drug may also have the potential to improve leukopaenia if used at a low dose.<\/jats:p>","DOI":"10.1136\/bcr-2013-010068","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T12:55:26Z","timestamp":1369313726000},"page":"bcr2013010068","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose ruxolitinib for improving leukopaenia and reducing recurrent infections associated with myelofibrosis"],"prefix":"10.1136","volume":"2013","author":[{"given":"Rezwan","family":"Islam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahender R","family":"Yellu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Rafiullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene R","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"key":"2025042707594860000_2013.may22_1.bcr2013010068.1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"2013","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/phar.1165","article-title":"Ruxolitinib: a new treatment option for myelofibrosis","volume":"2013","author":"Ganetsky","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"2013","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"2013","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"2013","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-8722-5-43","article-title":"Splenomegaly in myelofibrosis\u2014new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors","volume":"2013","author":"Randhawa","year":"2012","journal-title":"J Hematol Oncol"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.7","first-page":"583","article-title":"Modern management of myelofibrosis","volume":"2013","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.8","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"2013","author":"Mesa","year":"2009","journal-title":"Blood"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"2013","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"2013","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025042707594860000_2013.may22_1.bcr2013010068.11","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"2013","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-010068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T14:59:57Z","timestamp":1745765997000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-010068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":11,"alternative-id":["10.1136\/bcr-2013-010068"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-010068","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2013,5,22]]}}}